Fulcrum Therapeutics, Inc. (FULC)

Market Cap	529.01M
Revenue (ttm)	n/a
Net Income (ttm)	-71.11M
Shares Out	54.12M
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	774,626
Open	9.52
Previous Close	9.65
Day's Range	9.03 - 9.85
52-Week Range	2.32 - 10.11
Beta	3.18
Analysts	Buy
Price Target	10.43 (+6.7%)
Earnings Date	Oct 29, 2025

About FULC

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2019
• Employees: 45
• Stock Exchange: NASDAQ
• Ticker Symbol: FULC
• Website: https://www.fulcrumtx.com

Financial Performance

In 2024, Fulcrum Therapeutics's revenue was $80.00 million, an increase of 2752.05% compared to the previous year's $2.81 million. Losses were -$9.73 million, -90.01% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for FULC stock is "Buy." The 12-month stock price target is $10.43, which is an increase of 6.70% from the latest price.

Price Target

$10.43

(6.70% upside)

Analyst Consensus: Buy